• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Appili Therapeutics Inc (OP:APLIF)

0.0055 UNCHANGED
Delayed Quote Updated: 2:57 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 50
Open 0.0055
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0055
Today's Range 0.0055 - 0.0055
52wk Range 0.0041 - 0.0221
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Engages Spartan Capital as Lead Underwriter for Planned IPO
July 29, 2025
Via Investor Brand Network
Topics Initial Public Offering
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Invited to Submit Full Proposal for DoD-Funded Ovarian Cancer Diagnostic Study
July 24, 2025
Via Investor Brand Network

Performance

52-Week Range 75.1% below 52-week high
0.0055
0.0052W Low 0.0252W High

Appili Therapeutics Inc (APLIF) traded between $0.00 and $0.02 over the past 52 weeks and last traded at $0.01, 75.1% below its 52-week high.

Past 12 Months
N/A
-41.5%
-50.0%
-61.5%
-67.8%
-74.5%
1W  
1M -$0.00
3M -$0.01
6M -$0.01
YTD -$0.01
1Y -$0.02

APLIF was -74.5% over the past year, -61.5% over six months, -67.8% year to date.

12 Months vs Market
APLIF
-74.5%
DIA
+12.4%
SPY
+14.9%
QQQ
+17.5%
IWM
+11.1%

Over the past 12 months APLIF returned -74.5% versus DIA (Dow) +12.4%, SPY (S&P 500) +14.9%, QQQ (Nasdaq 100) +17.5% and IWM (Russell 2000) +11.1%.

Volume & Liquidity 0.01× 3-mo avg
Today 50 3-mo avg 7.0K
1W
50.0
1M
12.0
3M
7.0K
6M
16.2K
YTD
21.5K
1Y
20.1K

APLIF most recently traded 50 shares against a 3-month average daily volume of 7.0K.

More News

Read More
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Host July 22 Livestream on Autoimmune Therapeutics Subsidiary Adimune
July 22, 2025
Via Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) CEO to Present at Wall Street Reporter’s NEXT SUPER STOCK Event June 26
June 26, 2025
Via Investor Brand Network
TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Appoints Evofem CEO Saundra Pelletier to Board of Directors
June 09, 2025
Via Investor Brand Network
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Appoints Evofem CEO Saundra Pelletier to Board of Directors
June 09, 2025
Via Investor Brand Network
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Terminates Acquisition Agreement with Appili Therapeutics
May 19, 2025
Via Investor Brand Network
News headline image
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Highlights ADI-100 Developments in Weekly Update Featuring Leadership Team
May 02, 2025
Via Investor Brand Network
News headline image
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Host Mayo Clinic’s Dr. Charles Howe in May 2 Update on ADI-100™ Preclinical Study
April 17, 2025
Via Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Gains IRB Approval for Endometriosis Diagnostic Study
April 16, 2025
Via Investor Brand Network
News headline image
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Regains Nasdaq Compliance, Hearing Canceled
April 09, 2025
Via Investor Brand Network
News headline image
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Host Appili CEO in April 4 Update Focused on Infectious Disease Innovation
April 02, 2025
Via Investor Brand Network
News headline image
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Highlights CaSe Platform Acquisition in Weekly Update Focused on Early Cancer Detection
March 28, 2025
Via Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Acquires Patents for DNA Damage Detection in Cancer Prevention
March 24, 2025
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Provides Update on Appili Therapeutics Acquisition and Federal Funding Applications
March 18, 2025
Via Investor Brand Network
News headline image
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Provides Corporate Update, Announces Weekly Investor Series
March 17, 2025
Via Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Advances ADI-100 Autoimmune Therapy Toward Clinical Trials
March 06, 2025
Via Investor Brand Network
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Engages Lead Underwriter for Planned IPO
February 21, 2025
Via Investor Brand Network
Topics Initial Public Offering
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) to Host Fireside Chat on Feb. 21 to Discuss Key Corporate Developments
February 13, 2025
Via Investor Brand Network
Topics Initial Public Offering
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Explores IPO for Pearsanta to Advance Early Cancer Detection
January 13, 2025
Via Investor Brand Network
Topics Initial Public Offering
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Subsidiary Advances ADI-100 Gene Therapy Toward Human Trials
December 12, 2024
Via Investor Brand Network
News headline image
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
December 12, 2024
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Updates Shareholders on Equity Issuance and Shift to Debt Financing Strategy
November 08, 2024
Via Investor Brand Network
News headline image
Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
November 08, 2024
From Aditxt, Inc.
Via Business Wire
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Acquisition of Appili Therapeutics Moves Forward with Overwhelming Shareholder Approval
November 07, 2024
Via Investor Brand Network

Frequently Asked Questions

Is Appili Therapeutics Inc publicly traded?
Yes, Appili Therapeutics Inc is publicly traded.
What exchange does Appili Therapeutics Inc trade on?
Appili Therapeutics Inc trades on the OTC Traded
What is the ticker symbol for Appili Therapeutics Inc?
The ticker symbol for Appili Therapeutics Inc is APLIF on the OTC Traded
What is the current price of Appili Therapeutics Inc?
The current price of Appili Therapeutics Inc is 0.0055
When was Appili Therapeutics Inc last traded?
The last trade of Appili Therapeutics Inc was at 10/14/26 02:57 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap